SCHEDULE: ADAR1 Capital Discloses 24.1% Stake in InMed Pharma

ADAR1 Capital Management and Daniel Schneeberger have reported a 24.1% beneficial ownership stake in InMed Pharmaceuticals, Inc.

Summary

• ADAR1 Capital Management, LLC and Daniel Schneeberger filed a Schedule 13G reporting beneficial ownership of 800,000 common shares of InMed Pharmaceuticals, Inc.
• The reported stake represents 24.1% of the company's outstanding common shares.
• The ownership is held through private investment funds managed by ADAR1 Capital Management.
• The filing confirms the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive development, as it demonstrates significant institutional backing, though it does not provide new information regarding the company's operational performance.

Positives

• Significant institutional interest indicated by a 24.1% ownership stake.
• The reporting persons have certified that the shares were acquired in the ordinary course of business, suggesting a passive investment strategy.

Negatives

• High concentration of ownership (24.1%) by a single investment manager may lead to increased stock volatility if the firm decides to adjust its position.

Risks

• Potential for market impact if the reporting entity decides to divest a significant portion of its 800,000 shares.
• Reliance on the accuracy of the company's reported outstanding share count (3,314,063 as of May 4, 2026) for the percentage calculation.

Future Outlook

The filing does not provide specific forward-looking guidance regarding the company's operations, but confirms the reporting persons' intent to hold the shares passively.

Industry Context

StockSavvy.ai notes that large Schedule 13G filings in the pharmaceutical sector often signal institutional confidence in a company's pipeline or valuation, though they can also precede liquidity events or strategic shifts.

Comparison to Industry Standards

• A 24.1% stake is a substantial position for an investment manager, significantly higher than typical passive holdings which often hover between 5% and 10%.
• The filing follows standard regulatory requirements for institutional investors exceeding the 5% threshold.

Stakeholder Impact

• Shareholders may view the large stake as a sign of institutional support.
• Potential for increased share price volatility due to the concentration of ownership.

Next Steps

• Monitoring for any subsequent Form 4 filings if the reporting persons change their position or intent.

Key Dates

Recommendation

The filing indicates strong institutional interest, which is generally a positive signal, but investors should wait for further operational updates from the company before adjusting positions.

Keywords

InMed Pharmaceuticals, ADAR1 Capital Management, Schedule 13G, Beneficial Ownership, INM, Institutional Investor